Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Mimedx (MDXG) EBT Margin (2016 - 2025)

Historic EBT Margin for Mimedx (MDXG) over the last 16 years, with Q3 2025 value amounting to 20.09%.

  • Mimedx's EBT Margin rose 65100.0% to 20.09% in Q3 2025 from the same period last year, while for Sep 2025 it was 14.16%, marking a year-over-year decrease of 33300.0%. This contributed to the annual value of 16.42% for FY2024, which is 68900.0% up from last year.
  • As of Q3 2025, Mimedx's EBT Margin stood at 20.09%, which was up 65100.0% from 13.19% recorded in Q2 2025.
  • Over the past 5 years, Mimedx's EBT Margin peaked at 26.62% during Q2 2024, and registered a low of 17.7% during Q1 2022.
  • In the last 5 years, Mimedx's EBT Margin had a median value of 11.29% in 2023 and averaged 4.87%.
  • As far as peak fluctuations go, Mimedx's EBT Margin crashed by -135400bps in 2022, and later soared by 274500bps in 2023.
  • Over the past 5 years, Mimedx's EBT Margin (Quarter) stood at 0.18% in 2021, then soared by 7301bps to 13.25% in 2022, then rose by 21bps to 16.02% in 2023, then decreased by -24bps to 12.11% in 2024, then surged by 66bps to 20.09% in 2025.
  • Its EBT Margin stands at 20.09% for Q3 2025, versus 13.19% for Q2 2025 and 9.76% for Q1 2025.